Found: 45
Select item for more details and to access through your institution.
Moving Forward in Hormone-Refractory Prostate Cancer: From Understanding Biology to Advancing Therapy.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 2, p. 199
- By:
- Publication type:
- Article
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium.
- Published in:
- BJU International, 2010, v. 105, n. 3, p. 317, doi. 10.1111/j.1464-410X.2009.08799.x
- By:
- Publication type:
- Article
Interleukin-2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers.
- Published in:
- 1989
- By:
- Publication type:
- journal article
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
- Published in:
- 2020
- By:
- Publication type:
- journal article
New developments in the treatment of castration resistant prostate cancer.
- Published in:
- Asian Journal of Andrology, 2014, v. 16, n. 4, p. 555, doi. 10.4103/1008-682X.127824
- By:
- Publication type:
- Article
Proteolysis-Targeting Chimera (PROTAC) Therapy for Cancer.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 12, p. 849
- By:
- Publication type:
- Article
Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 4, p. 166, doi. 10.46883/onc.2021.3504.0166
- By:
- Publication type:
- Article
Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care: Part 1: The Non-Androgen--Targetable Pathways in Castration-Resistant Prostate Cancer.
- Published in:
- Oncology (08909091), 2019, v. 33, n. 3, p. 113
- By:
- Publication type:
- Article
Novel Targets and Precision Medicine For Prostate Cancer: Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
- Published in:
- Oncology (08909091), 2019, v. 33, n. 4, p. 128
- By:
- Publication type:
- Article
Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial Cancer.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 3, p. 132
- By:
- Publication type:
- Article
New Agents for the Treatment of Advanced Bladder Cancer.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 6, p. 571
- By:
- Publication type:
- Article
Sequencing of Agents for Castration-Resistant Prostate Cancer.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 11, p. 1144
- By:
- Publication type:
- Article
The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy.
- Published in:
- 2013
- By:
- Publication type:
- Case Study
Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases: Mechanism of Action of Radium-223 Chloride (Alpharadin) and Radiation Protection.
- Published in:
- Oncology (08909091), 2012, v. 26, n. 4, p. 330
- By:
- Publication type:
- Article
Evolving Therapeutic Paradigms for Advanced Prostate Cancer: What's Needed to Make Optimal Use of the New Treatments.
- Published in:
- Oncology (08909091), 2011, v. 25, n. 6, p. 514
- By:
- Publication type:
- Article
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.
- Published in:
- JNCI Cancer Spectrum, 2020, v. 4, n. 2, p. 1, doi. 10.1093/jncics/pkaa003
- By:
- Publication type:
- Article
Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2006, v. 98, n. 8, p. 516, doi. 10.1093/jnci/djj129
- By:
- Publication type:
- Article
Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 7, p. 3182, doi. 10.1111/bcp.15233
- By:
- Publication type:
- Article
Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.
- Published in:
- Oncogene, 2003, v. 22, n. 10, p. 1431, doi. 10.1038/sj.onc.1206258
- By:
- Publication type:
- Article
Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 3, p. 2761, doi. 10.1002/cam4.5165
- By:
- Publication type:
- Article
Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 5, p. 319, doi. 10.1177/1758834017698644
- By:
- Publication type:
- Article
Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2009, v. 1, n. 2, p. 69, doi. 10.1177/1758834009343454
- By:
- Publication type:
- Article
Intermittent Chemotherapy in Patients With Metastatic Androgen-Independent Prostate Cancer.
- Published in:
- Cancer (0008543X), 2008, v. 112, n. 2, p. 326, doi. 10.1002/cncr.23163
- By:
- Publication type:
- Article
A pilot study of the vulnerable elders survey‐13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablationPresented in part as a poster at the Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia, June 2–6, 2006.
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 4, p. 802, doi. 10.1002/cncr.22495
- By:
- Publication type:
- Article
Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinoma: A Southwest Oncology Group studyAddress for reprints: Southwest Oncology Group (SWOG‐9457), Operations Office, 14980 Omicron Dr., San Antonio, TX 78245‐3217; Fax: (210) 677‐0006; E‐mail: pubs@swog.org
- Published in:
- Cancer (0008543X), 2005, v. 104, n. 8, p. 1627
- By:
- Publication type:
- Article
Southwest Oncology Group studies in bladder cancer (Based on a Satellite Symposium held in conjunction with the First European Conference on Perspectives in Bladder Cancer, Monte Carlo, Monaco, November 1617, 2001.).
- Published in:
- Cancer (0008543X), 2003, v. 97, p. 2099
- By:
- Publication type:
- Article
A Phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 3, p. 537, doi. 10.1002/cncr.11082
- By:
- Publication type:
- Article
PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study.
- Published in:
- Prostate, 2020, v. 80, n. 1, p. 99, doi. 10.1002/pros.23922
- By:
- Publication type:
- Article
Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer.
- Published in:
- Prostate, 2019, v. 79, n. 6, p. 604, doi. 10.1002/pros.23765
- By:
- Publication type:
- Article
A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Third Joint Meeting of the American Urological Association and the Japanese Urological Association International Program at the 103rd Annual Meeting of the American Urological Association at Orlando 2008.
- Published in:
- 2008
- By:
- Publication type:
- Other
Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer.
- Published in:
- BJU International, 2021, v. 127, n. 4, p. 435, doi. 10.1111/bju.15227
- By:
- Publication type:
- Article
The utility of prostate-specific antigen in the management of advanced prostate cancer.
- Published in:
- BJU International, 2013, v. 112, n. 5, p. 548, doi. 10.1111/bju.12061
- By:
- Publication type:
- Article
Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer.
- Published in:
- PLoS ONE, 2016, v. 11, n. 5, p. 1, doi. 10.1371/journal.pone.0154507
- By:
- Publication type:
- Article
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
- Published in:
- Nature, 2014, v. 515, n. 7528, p. 558, doi. 10.1038/nature13904
- By:
- Publication type:
- Article
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00417-5
- By:
- Publication type:
- Article
Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.
- Published in:
- 2017
- By:
- Publication type:
- journal article
An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 7, p. 976, doi. 10.1002/cncr.28519
- By:
- Publication type:
- Article
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 5, p. 692, doi. 10.1002/cncr.28477
- By:
- Publication type:
- Article
A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 2, p. 358, doi. 10.1002/cncr.26278
- By:
- Publication type:
- Article
High dose calcitriol may reduce thrombosis in cancer patients.
- Published in:
- British Journal of Haematology, 2006, v. 135, n. 3, p. 392, doi. 10.1111/j.1365-2141.2006.06322.x
- By:
- Publication type:
- Article
What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.951348
- By:
- Publication type:
- Article
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Immunotherapy for Urological Malignancies: Evolution of End Points and Future Directions.
- Published in:
- AUANews, 2017, v. 22, n. 1, p. 3
- By:
- Publication type:
- Article